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ABSTRACT
Objective: Oral secretions can be a debilitating symptom for patients with ALS, but the
treatment of this symptom is poorly defined and opinions on best practice are diverse. The
objective of this study was to identify the treatments that are commonly prescribed, and to
describe how experienced clinicians approach a patient with symptoms resistant to
treatment.
Methods: Twenty-three clinicians were approached - nineteen clinicians from 16 centres
across the UK provided case report forms for a total of 119 ALS patients, who were
identified as having treatment for a secretion problem.
Results: The use of 5 types of anticholinergics, salivary gland botulinum toxin injections,
conservative management approaches and carbocisteine were reported. Of the cases
reviewed, 61% had symptomatic improvement following the introduction of a first
anticholinergic. Only 19% of patients achieved any symptomatic improvement with the use
of an alternative anticholinergic when an initial anticholinergic achieved no symptomatic
improvement. There was marked variation in the doses of the anticholinergics prescribed.
Combinations of anticholinergic drugs were used in 16 patients. Botulinum toxin injections
into the salivary glands were used in 17 patients, chosen particularly in those who had
failed to achieve a good level of secretion control with the use of anticholinergic medication
and reported to improve symptoms in 57% of patients.
Conclusion: There are a variety of treatment options in use for oral secretion problems in
ALS patients but the variation in management approaches highlights the need for further
research in this area.
Search terms: Secretion management, sialorrhea, anticholinergics, botulinum toxin
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
affecting the motor nerves supplying the limbs, trunk, bulbar region and respiratory
muscles.[1]
It has been estimated that 50% of ALS patients suffer from saliva problems and a
recent survey of clinicians estimated that in 42% of patients with secretion problems,
these problems are poorly controlled.[2]
Symptoms and consequences include drooling (sialorrhea), breakdown of the skin
around the mouth, speech disturbance, disruption of sleep, coughing and a higher
risk of aspiration. These problems can lead to psychosocial symptoms including
distress, embarrassment and social withdrawal.[3, 4]
Treatment is usually determined by clinician experience and includes treatments
include anticholinergics, botulinum toxin, radiotherapy and surgery. [3, 5 - 19]
However, the studies evaluating these therapies are to an extent limited by lack of
blinding, few participants and the use of outcome measures not designed for patients
with ALS.[7, 13, 20 - 22] It should also be noted that the treatment of sialorrhea by
any of these medications is unlicensed in the UK.
Patients with ALS also often suffer from problems with the collection of thick
secretions in their throat and respiratory tract. These thick secretions may develop or
be exacerbated following the treatment of excessive runny saliva. [6]
In the absence evidence-based guidelines, sharing experience and practice amongst
clinicians is an approach which can be used to develop a better understanding of the
merits of available treatments. In this paper we explore treatment approaches that
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have been devised by neurologists working at amyotrophic lateral sclerosis care
centres across the UK.
The aims of this study were to identify:
 Which therapies were used to manage oropharyngeal secretion problems?
 How the different treatment options were used in combination.
 Treatment approaches in patients with symptoms resistant to initial management.
 The type and impact of adverse effects in patients being treated for secretion
problems.
METHODS AND PATIENTS
We conducted a retrospective cohort study, involving a review of the notes of
patients identified to have a secretion problem. A case report form (CRF) for
recording individual secretion management regimens, was circulated to 23 ALS care
centre physicians with a special interest in the care of ALS patients from across the
UK. These clinicians were asked to complete a case report using information
recorded in the clinical record, for each consecutive patient they saw in clinic with a
current or previous secretion problem, during the period between 01/12/2012 and
01/04/2013. This approach reduced recall and selection bias.
A secretion problem was defined as:
 Excessive saliva in a patient’s mouth which may cause drooling.
 The sensation of thicker secretions in the patient’s throat which results in a
choking like discomfort.
During the census period, data was collected from patients attending clinics with a
new secretion problem, and from patients attending clinics where they were followed
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up for an existing secretion problem. Descriptive statistics were used to present the
data. The treatments prescribed to patients with a secretion problem were recorded.
When the patient had attended for follow up of a secretion problem, the side effects
and the perceived benefit on symptoms of any treatment reported to the clinician
were recorded.. If there was no record concerning the effect on symptoms, these
cases have been omitted from the descriptive statistic of the effect of treatment on
symptoms.
RESULTS
One-hundred and nineteen patients were identified as having a secretion problem
during the study period. Patient demographics are shown in Table 1. The type of
secretion problem that had been experienced by the patients were reported to be: a
problem with only excessive saliva in 48 patients (40%); a problem only with thicker
secretions in 27 (23%); and a combination of both types of secretion problem in 44
(37%).
Problems with excessive saliva were reported to have been managed with
anticholinergic drugs and salivary gland botulinum toxin injections. We identified five
different types of anticholinergic drug used to manage problems with excessive thin
saliva in the 92 patients who were reported to have a problem with excessive saliva.
These were hyoscine hydrobromide (transdermal patch or oral preparation), oral
amitriptyline, atropine (sublingual drops, transdermal patch, or tablets), oral
propantheline, and oral glycopyrronium.
The most common first line treatment reported to have been used to manage
problems with excessive saliva was the prescription of an anticholinergic, used in all
92 patients. For 13/92 of the patients, the visit during the data collection period was
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the first identification a problem with excessive saliva and consequent prescription of
an anticholinergic, therefore no follow up data was available. In 72/92, patients had
been prescribed the anticholinergic at a previous appointment and had an effect on
symptoms recorded at a follow up appointment. In these patients 44/72 (61%) had
an improvement in symptoms recorded and in 28/72 it was recorded that the initial
anticholinergic had not improved symptoms. In total, 79 patients had been seen
again since the prescription of the initial anticholinergic, but in seven the effect of this
treatment on symptoms had not been recorded. In these 79 patients side effects
were reported in 54%. (Figure 1)
The most frequently used first line anticholinergics were hyoscine patches (56),
amitriptyline (15) and atropine drops (11). Symptoms were reported to have
improved in some patients following treatment with each of the types of first line
anticholinergic, with rates ranging from 50% to 89% [Figure 2].
Of the 28/72 patients (39%) whose symptoms were reported to not have improved
following an initial anticholinergic, 22 tried another anticholinergic. 21 of these
patients had been seen again and had the second anticholinergics effect on their
excessive saliva symptoms recorded, only four of whom (19%) had symptomatic
improvement documented in their notes.
Sixteen patients were given a combination of two anticholinergics after a first
anticholinergic was reported to improve symptoms but not sufficiently to adequately
control the problem over time. Of the 11 with an effect on symptoms recorded, five
patients symptoms had improved (45%) and six (55%) had not. Seven of the 13
(54%) patients who had been seen again since starting combination anticholinergic
therapy had adverse effects to this treatment documented in their notes. Three of
McGeachan 10
these patients had not yet been seen again since the addition of a second
anticholinergic and two had returned to clinic but the treatments effect on symptoms
was not reported. Two patients were then given three anticholinergics in combination.
Different anticholinergic medications were prescribed on 161 occasions as a first,
second, third or 4th line treatment for excessive saliva. Overall, anticholinergic
treatment was recorded to improve symptoms in a proportion of patients ranging
from 43% to 63% [Figure 3]. As previously described, the information about the
effect of treatment on symptoms was not available for all patients who had been
prescribed each drug. Whilst atropine drops and the hyoscine patch were generally
used first line, glycopyrronium was generally used as a second line treatment [Figure
4]. The doses of anticholinergics which were prescribed were highly variable [Table
4]. The commonly used hyoscine patch was usually prescribed as either a full (n=54)
or a half (n=10) 1mg patch per 72 hours. Symptomatic improvement was recorded in
all seven patients with an outcome recorded after starting a half path.
Side effects were commonly reported with the use of anticholinergic medications.
Undesired anticholinergic effects were frequently reported including an excessively
dry mouth, confusion, drowsiness and urinary retention [Table 2]. In addition,
hyoscine patches were reported to cause with a skin reaction at the patch site in 22%
of these patients [Table 2], causing treatment discontinuation in 18% of those using
hyoscine patches. Only one patient was reported to have tried to control these skin
reactions, they applied topical steroid to the site of the reaction between patch
applications, enabling them to persist with the patch. Overall 33% of patients
discontinued hyoscine patches due to intolerable adverse effects. Sublingual
atropine drops and oral glycopyrronium had lower reported rates of adverse effects,
24% and 28% respectively compared to the 60% reported for hyoscine patches
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[Table 2]. As previously described the information about the effect of treatment on
symptoms was not available for all patients who had been prescribed each drug.
Botulinum toxin was used in 17/119 (14%) of patients with a secretion problem
across 10 centres. In 14/17 patients (82%) botulinum toxin was used 3rd line or later.
Two patients received these injections under ultrasound guidance, and the time
between the decision to give botulinum toxin injections and its administration varied
from same day administration to 12 weeks later. In total, three brands (Dysport,
Neurobloc, and Botox A) and 12 different dosing regimens of botulinum toxin were
used, including injection of both the parotid and submandibular glands and parotid
gland only injections. The doses of botulinum toxin ranged from 60 units of Dysport
to 3000 units of Neurobloc [Table 4]. Despite being used in situations where
symptoms were uncontrolled by anticholinergics, symptomatic improvement was
documented in 8 (57%) of the 14 patients who had an outcome on symptoms
recorded, demonstrating the usefulness of this intervention in patients with difficult to
control symptoms. Three patients had not been seen again since treatment with
botulinum toxin.
Of the 17 patients who had received an initial treatment with botulinum toxin
injections, seven had already opted to receive additional injections and five had
chosen to discontinue the injections following just one treatment. The reason for
discontinuation was unacceptable side effects in one patient, inadequate symptom
control in two, a combination of inadequate symptom control and unacceptable side
effects in one, and one patient being unable to attend clinic. Two patients continued
to use anticholinergic medication alongside botulinum toxin injections for ‘top up’
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symptom control in between their botulinum toxin injections. Three patients were
using carbocisteine syrup in addition to botulinum toxin injections to combat
thickened secretions.
Of the 14 patients who had been followed up since receiving salivary gland
botulinum toxin injections, 50% had experienced adverse effects. This included two
cases of deteriorating bulbar function which in the clinician’s opinion was not due to
disease deterioration. One of these cases was following injections to the parotid and
submandibular glands and one following injections only into the parotid glands.
Problems with thick secretions were also frequently reported to be a problem in this
ALS population. In total, 71 patients had suffered with thick secretions, in the
absence of excessive thin secretions (27 patients), or alongside this problem (44
patients), possibly as a consequence of treatment with anticholinergic drugs or
botulinum toxin. Carbocisteine syrup was prescribed to 45 of these patients and
symptomatic relief was reported in 27 of 31 patients (87%) with an outcome
recorded. In total, seven patients (19%) reported adverse effects when using
carbocisteine including constipation (6%), excessive dryness in the mouth (6%),
vomiting (2%), and worsening of thin secretion problems (2%), and further
deterioration of thick secretion problems (2%). Conservative measures were also
commonly used to manage thick secretions [Table 3].
Forty-six (39%) received some conservative therapy, some directed at excessive
saliva and some at thickened secretion. This included the use of suctioning, reported
to be useful in 15 (68%) of the 22 patients it was used in, and maintaining adequate
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hydration, which was reported to be useful for all 6 of the patients who had this
intervention documented [Table 3].
DISCUSSION
In the absence of a cure for ALS, an important aspect of management is to control
symptoms in order to maximise patients’ quality of life.[6, 23]
Hyoscine patches were the most frequently used therapy for excessive saliva, a
choice which is often made because of the ease of use of patches.[2] However,
hyoscine patches were frequently associated with adverse effects (60%), in
particular, a skin reaction to the patch. Rate of hyoscine patch discontinuation due to
adverse effects was 33% and often due to this skin reaction, considerably higher
than the 13% discontinuation rate reported in a previous study of hyoscine patch use
in children.[24] The suggestion that topically applied steroids could reduce this skin
reaction may be a way in which the tolerability of this simple but effective treatment
could be improved. As anticholinergics are so commonly associated with adverse
effects and symptomatic improvement was reported at lower doses, it may be most
appropriate to always start at a low dose and titrate up as necessary and tolerated.
The use of glycopyrronium was generally preferred second line. Perhaps further
consideration could be given to this treatment as a first line option, especially given
its relatively low rates of adverse effects due in part to poor penetration across the
blood brain barrier. [25]
Interestingly, of those patients whose symptoms did not improve when using a first
anticholinergic, only 19% had a symptomatic improvement if they tried an alternative.
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Further work is needed to determine which treatments are appropriate if an initial
anticholinergic is ineffective. In comparison, 45% of patients had symptomatic
improvement reported when they started a second anticholinergic alongside their
initial anticholinergic, when the first was reported to have improved symptoms but
not control them sufficiently. In these patients side effects were reported in 54%,
rates similar to those seen with the overall use of anticholinergics. The switching and
combination of anticholinergics was common place in this study but is not well
discussed in the literature and deserves further exploration. [3, 6, 19]
In line with the limited recommendations for saliva management, clinicians primarily
chose botulinum toxin to treat patients with symptoms inadequately controlled by
anticholinergic treatment. [5, 19] The 57% rates of symptomatic improvement
reported in this study support the use of this treatment in such patients. There was a
vast range of practice in the dose and injection site of the botulinum toxin. The
biological activity of Dysport is 50 times that of Neurobloc meaning that the most
commonly prescribed dose of Dysport (100 Units) has twice the activity of the most
commonly prescribed dose of Neurobloc (2500 units). [26] With such variety in
dosing and injection sites it is difficult to compare the efficacy, side effects and safety
of this treatment.
With the use of botulinum toxin, there is concern about consequential deterioration of
bulbar function,[2] such deterioration was reported in 14% of patients in this study.
Despite greater anatomical distance between the parotid glands and the bulbar
muscles compared to the submandibular glands, deterioration in bulbar function was
also reported following parotid gland only injections. Bulbar deterioration could be a
result of disease progression, however, in these cases the clinicians had specifically
documented that the post injection deterioration in function was in their opinion a
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consequence of the injection. The safety and efficacy of botulinum toxin injections
need to be further assessed to enable clinicians to judge the risks to the benefits for
their patients.
Whilst there are studies suggesting that salivary gland irradiation may an effective
treatment, its use was not reported in this study. [27] Additionally, no surgical options
were used; this may reflect the invasive and irreversible nature of these interventions.
A high proportion of patients were suffering from both thick and thin secretion
problems, and thickened secretions were one of the most commonly reported side
effects of the treatments for excessive saliva. A fine balance must be struck between
the management of the different types of secretion problem. It would be useful for
future studies to identify optimal practice for patients with different oral secretion
profiles.
Despite remaining relatively unaddressed in many review and guideline articles, [3, 6,
5, 19] the use of conservative measures was often reported as part of the
management for both thick and thin secretions. These are largely simple
interventions which can be considered from the early stages of a secretion problem.
A review of sialorrhea management by Hockstein et al. in 2005 highlights a number
of possible conservative measures. [21]
Carbocisteine was the preferred medication for managing problems with thickened
secretions, with high reported rates of symptomatic relief and infrequent adverse
effects. This was often supplemented with conservative therapies such as using
saline nebulisers.
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The major limitation when conducting this study was the retrospective nature of the
data collection. In the absence of a standardised follow up or outcome measure
being used to assess the patients with secretion problems, it was not possible to
determine the extent of any symptomatic improvement or severity of any adverse
effects. Moreover, it is possible that not all side effects were reported to the
physician and so rates of these may be higher than reported. As a result, it was not
possible to compare one treatment to another.
A previous study of UK secretion management estimated that the centres invited to
participate in this study cared for 73% of the patients with a new diagnosis of ALS in
2012.[2] However, this study only represents clinicians managing secretion problems
in UK and therefore neglects treatments such as radiotherapy and tracheostomy
which are commonly used outside of the UK. [28, 29]
Conclusion
Future work is needed to determine which treatment options are most effective and
best tolerated for managing oropharyngeal secretion problems in ALS. Simple data
has been presented in this study to provide baseline information about the
treatments in use in the UK, which we hope will facilitate effective design of further
studies to answer these questions.
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Table Legend
Table 1: Summary of the demographics of the patients whose secretion problem
management was recorded in this study.
Table 2: Rates of reported adverse effects in patients receiving treatment for
excessive saliva.
Table 3: Summary of the relative merits of the various conservative measures for
secretion management and the type of secretion problem they were used to treat.
Table 4: Summary of the dose variation of the treatments prescribed for the
management of oral secretions.
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Figure Legend
Figure 1: Availability of outcome data for when patients received a first
anticholinergic: Summarising why not all patients who were prescribed an
anticholinergic had efficacy data recorded.
Figure 2: Proportion of patients who had a documented symptomatic
improvement when receiving a first line anticholinergic for excessive saliva:
Summarising the percentage of patients, out of the patients who had an outcome to
treatment recorded in their notes (improvement or no improvement), whose
symptoms were documented to have improved when using each anticholinergic.
Figure 3: Proportion of patients who had a documented symptomatic
improvement when receiving a treatment for excessive saliva: Summarising the
percentage of patients, out of the patients who had an outcome to treatment
recorded in their notes (improvement or no improvement), whose symptoms were
documented to have improved when using each anticholinergic.
Figure 4: Frequency of the various anticholinergics prescribed for secretion
management: Summarising the number of times each anticholinergic was
documented to have been prescribed to patients for the control of a secretion
problem. Data is broken down to present the frequency each anticholinergic was
prescribed as a 1st, 2nd or 3rd line or later treatment.
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Tables:
Table 1: Patient demographics (n=119)
Age Mean (Range) 64 years (40-86 years)
Gender Male 50%
Disease Duration Median (Range) 2.2 years (0.1 – 15.9)
Bulbar onset disease 50%
Gastrostomy 44%
NIV 18%
Cough Assist 7%
Last ALSFRS-r Score
when available (n=88)
Mean (Range) 28/48 (3-45)
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* One patient (14%) using oral hyoscine reported an excessively dry mount (n=7)
* Infrequently prescribed anticholinergic preparations (n<3) have been omitted from
this table
Table 2: Rates of reported adverse effects in patients receiving treatment for
excessive saliva:
Hyoscine
Patches
(n=57)
Amitriptyline
(n= 25)
Atropine
drops
(n= 21)
Oral
Glycopyrronium
(n= 17)
Botulinum
toxin
injections
(n=14)
Excessively Dry
Mouth 6 (11%) 5 (20%) 3 (14%) 2 (12%) 1(7%)
Thickened
Secretions 10 (18%) 3 (12%) 2 (10%) 2 (12%) 5 (36%)
Skin Reaction 12 (22%) 0 0 0 0
Confusion 5 (9%) 0 0 0 0
Drowsiness 6 (9%) 8 (32%) 0 0 0
Dizziness 4 (5%) 2 (8%) 0 0 0
Light headed 4 (5%) 2 (8%) 0 0 0
Nausea 3 (5%) 0 0 0 0
Urinary
Retention
1 (2%) 1 (4%) 0 0 0
Bulbar
dysfunction
0 0 0 0 2 (14%)
Overall
proportions
34 (60%) 12 (48%) 6 (29%) 4 (24%) 7 (50%)
Proportion who
discontinued
due to adverse
effects
33% 12% 6% 5% 13%
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Table 3: Summary of the relative merits of the various conservative measures
for secretion management and the type of secretion problem they were used to
treat
Total
Used
Useful Maybe
Useful
Not
useful
Therapies for
thinning out
secretions
Steam
nebulisers
19 11 (58%) 4 (21%) 4
(21%)
Fruit juice 16 7 (43%) 7 (43%) 2
(14%)
Papaya 9 5 (56%) 3 (33%) 1
(11%)
Hydration 6 6
(100%)
0 0
Swabs 5 3 (60%) 0 2
(40%)
Therapies for
managing
excessive
secretions
Speech therapy 22 12 (52%) 6 (26%) 5
(22%)
Suction 22 15 (68%) 3 (14%) 4
(18%)
Swallow
reminders
11 6 (55%) 4 (36%) 1 (9%)
Positioning collar 9 3 (33%) 3
(33%)
3
(33%)
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Table 4: Summary of the dose variation of the treatments prescribed for
the management of oral secretions
Number of
different doses
Dose range Most common
dose
Anticholinergic
medications
Hyoscine Patch
(n=69)
8 ¼ of 1mg patch per 72
hours – 1 ½ 1mg patch per
24 hours
1mg patch per 72
hours
Oral Hyoscine
(n=8)
4 0.15mg TDS – 0.3mg TDS 0.3mg TDS
Amitriptyline
(n=25)
13 10mg ON – 175mg 10mg ON
Sublingual
Atropine Drops
(n=24)
15 1% solution 2 drops ON –
1% solution 2 drops QDS
1-2 drops TDS
Glycopyrronium
(n=19)
13 02.mg BD – 3mg TDS 1mg TDS
Botulinum
Toxin
Dysport 12 60U – 400U 100U
Neurobloc 6 1000U – 3000U 2500U
BOTOX A 2 14U – 100U Each used once
Mucolytics
Carbocisteine 7 125mg TDS – 750mg TDS 375mg TDS
*U = Units; ON = Once nightly; BD = twice daily; TDS = 3 times daily; QDS = 4 times
daily
*The 175mg dose of amitriptyline was prescribed by GP for emotional labiality.
* Infrequently prescribed anticholinergic preparations (n<3) have been omitted from
this table
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Figures
Figure 1
92 patients who were
prescribed an initial
anticholinergic drug
79 of these had had
the anticholinergic
prescribed at a
previous clinic
appointment and
were attending for
follow up at the clinic
when the data was
collected
72 patients had an
outcome documented
in the case report
forms
For 7 patients no
information about the
effect of this
anticholinergic was
documented in the
case report form
13 patients had this
drug prescribed for the
first time at the clinic
appointment
No data on the effect
of the anticholinergic
was available for
these patients
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Figure 2
* Infrequently prescribed anticholinergic preparations (n<5) have been omitted from
this table
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Figure 3
* Infrequently prescribed anticholinergic preparations (n<5) have been omitted from
this table
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Figure 4
* Infrequently prescribed anticholinergic preparations (n<5) have been omitted from
this figure
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Appendix
Case report form sent to clinicians
